Award

National Cancer Institute 5R01CA285468-03

First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers

Recipient

University of Maryland Baltimore

Award Amount

$641,126.00

Ceiling

$641,126.00

Awarded

December 22, 2025

Identifier

5R01CA285468-03

Development of small molecule inhibitors targeting hnRNP A18 to inhibit cancer progression and immune evasion.

Description

This project aims to develop small molecule inhibitors of hnRNP A18, a regulator of protein translation in cancer cells. These inhibitors are expected to block transcripts involved in cancer progression, metastasis, angiogenesis, anti-apoptosis, and immune checkpoints, thereby reducing tumor growth and immune evasion.

View original record